Drug class
Antineoplastic isocitrate dehydrogenase-1 (IDH1) inhibitors are a targeted class of small-molecule antineoplastic agents designed to selectively inhibit mutated IDH1 enzymes. Read more about Antineoplastic - Isocitrate Dehydrogenase-1 Inhibitor (IDH1)
3 drugs in this class 2 manufacturers
Antineoplastic isocitrate dehydrogenase-1 (IDH1) inhibitors are a targeted class of small-molecule antineoplastic agents designed to selectively inhibit mutated IDH1 enzymes.
By blocking the abnormal catalytic activity of mutated IDH1, these agents decrease the pathologic accumulation of the oncometabolite D-2-hydroxyglutarate, reversing epigenetic dysregulation and restoring normal cellular differentiation.
Agents in this class—such as ivosidenib and olutasidenib—are primarily indicated for the treatment of hematologic and solid malignancies harboring susceptible IDH1 mutations, notably acute myeloid leukemia, myelodysplastic syndromes, and locally advanced or metastatic cholangiocarcinoma.
Antineoplastic isocitrate dehydrogenase-1 (IDH1) inhibitors are a targeted class of small-molecule antineoplastic agents designed to selectively inhibit mutated IDH1 enzymes
Antineoplastic isocitrate dehydrogenase-1 (IDH1) inhibitors are a targeted class of small-molecule antineoplastic agents designed to selectively inhibit mutated IDH1 enzymes
By blocking the abnormal catalytic activity of mutated IDH1, these agents decrease the pathologic accumulation of the oncometabolite D-2-hydroxyglutarate, reversing epigenetic dysregulation and restoring normal cellular differentiation
By blocking the abnormal catalytic activity of mutated IDH1, these agents decrease the pathologic accumulation of the oncometabolite D-2-hydroxyglutarate, reversing epigenetic dysregulation and restoring normal cellular differentiation
Agents in this class—such as ivosidenib and olutasidenib—are primarily indicated for the treatment of hematologic and solid malignancies harboring susceptible IDH1 mutations, notably acute myeloid leukemia, myelodysplastic syndromes, and locally advanced or metastatic cholangiocarcinoma
Agents in this class—such as ivosidenib and olutasidenib—are primarily indicated for the treatment of hematologic and solid malignancies harboring susceptible IDH1 mutations, notably acute myeloid leukemia, myelodysplastic syndromes, and locally advanced or metastatic cholangiocarcinoma
Following a drug class requires a free Physicians Office Resource account.
